Details for New Drug Application (NDA): 202258

✉ Email this page to a colleague

NDA 202258 describes VICTRELIS, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are three patents protecting this drug. Additional details are available on the VICTRELIS profile page.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

Summary for 202258

Tradename:	VICTRELIS
Applicant:	Merck Sharp Dohme
Ingredient:	boceprevir
Patents:	3

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 202258

Generic Entry Date for 202258^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	CAPSULE;ORAL			Strength	200MG
Approval Date:	May 13, 2011	TE:		RLD:	No
Patent:	⤷ Sign Up	Patent Expiration:	Nov 11, 2027	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
Patent:	⤷ Sign Up	Patent Expiration:	Mar 17, 2027	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
Patent:	⤷ Sign Up	Patent Expiration:	Dec 22, 2024	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE

Expired US Patents for NDA 202258

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for 202258

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 202258

Profile for product number 001

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 202258